CoChat

Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment

Yapislar, Hande, Gurler, Esra Bihter · 2024 · Biomedicines
Cited by 64

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Diabetes mellitus is a chronic metabolic disorder characterized by high blood sugar levels, which can lead to severe health issues if not managed effectively. Recent statistics indicate a significant global impact, with 463 million adults diagnosed worldwide and this projected to rise to 700 million by 2045. Type 1 diabetes is an autoimmune disorder where the immune system attacks pancreatic beta cells, reducing insulin production. Type 2 diabetes is primarily due to insulin resistance. Both types of diabetes are linked to severe microvascular and macrovascular complications if unmanaged. Microvascular complications, such as diabetic retinopathy, nephropathy, and neuropathy, result from damage to small blood vessels and can lead to organ and tissue dysfunction. Chronic hyperglycemia plays a central role in the onset of these complications, with prolonged high blood sugar levels causing extensive vascular damage. The emerging treatments and current research focus on various aspects, from insulin resistance to the intricate cellular damage induced by glucose toxicity. Understanding and intervening in these pathways are critical for developing effective treatments and managing diabetes long term. Furthermore, ongoing health initiatives, such as increasing awareness, encouraging early detection, and improving treatments, are in place to manage diabetes globally and mitigate its impact on health and society. These initiatives are a testament to the collective effort to combat this global health challenge.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines12091958

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 138

  1. Wild, 2004, Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030, Diabetes Care, 27, 1047, 10.2337/diacare.27.5.1047 · DOI · Paper page
  2. Martinez-Ortega, A.J., Munoz-Gomez, C., Gros-Herguido, N., Remon-Ruiz, P.J., Acosta-Delgado, D., Losada-Vinau, F., Pumar-Lopez, A., Mangas-Cruz, M.A., Gonzalez-Navarro, I., and Lopez-Gallardo, G. (2022). Description of a Cohort of Type 1 Diabetes Patients: Analysis of Comorbidities, Prevalence of Complications and Risk of Hypoglycemia. J. Clin. Med., 11. · DOI
  3. Dabelea, 2009, The accelerating epidemic of childhood diabetes, Lancet, 373, 1999, 10.1016/S0140-6736(09)60874-6 · DOI · Paper page
  4. Li, 2007, Common pathological processes in Alzheimer disease and type 2 diabetes: A review, Brain Res. Rev., 56, 384, 10.1016/j.brainresrev.2007.09.001 · DOI · Paper page
  5. Nguyen, T.T., Ta, Q.T.H., Nguyen, T.K.O., Nguyen, T.T.D., and Giau, V.V. (2020). Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease. Int. J. Mol. Sci., 21. · DOI · Paper page
  6. Soyoye, 2021, Diabetes and peripheral artery disease: A review, World J. Diabetes, 12, 827, 10.4239/wjd.v12.i6.827 · DOI · Paper page
  7. Vithian, 2010, Microvascular complications: Pathophysiology and management, Clin. Med., 10, 505, 10.7861/clinmedicine.10-5-505 · DOI
  8. Zakir, 2023, Cardiovascular Complications of Diabetes: From Microvascular to Macrovascular Pathways, Cureus, 15, e45835
  9. Marcovecchio, 2011, Role of chronic and acute hyperglycemia in the development of diabetes complications, Diabetes Technol. Ther., 13, 389, 10.1089/dia.2010.0146 · DOI
  10. Brownlee, 2005, The pathobiology of diabetic complications: A unifying mechanism, Diabetes, 54, 1615, 10.2337/diabetes.54.6.1615 · DOI · Paper page
  11. Brownlee, 2001, Biochemistry and molecular cell biology of diabetic complications, Nature, 414, 813, 10.1038/414813a · DOI · Paper page
  12. Kowalczyk, P., Sulejczak, D., Kleczkowska, P., Bukowska-Osko, I., Kucia, M., Popiel, M., Wietrak, E., Kramkowski, K., Wrzosek, K., and Kaczynska, K. (2021). Mitochondrial Oxidative Stress-A Causative Factor and Therapeutic Target in Many Diseases. Int. J. Mol. Sci., 22. · DOI · Paper page
  13. Tang, W.H., Martin, K.A., and Hwa, J. (2012). Aldose reductase, oxidative stress, and diabetic mellitus. Front. Pharmacol., 3. · DOI · Paper page
  14. Singh, M., Kapoor, A., and Bhatnagar, A. (2021). Physiological and Pathological Roles of Aldose Reductase. Metabolites, 11. · DOI · Paper page
  15. Lorenzi, 2007, The polyol pathway as a mechanism for diabetic retinopathy: Attractive, elusive, and resilient, Exp. Diabetes Res., 2007, 61038, 10.1155/2007/61038 · DOI · Paper page
  16. Khalid, M., Petroianu, G., and Adem, A. (2022). Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Biomolecules, 12. · DOI · Paper page
  17. Yamagishi, 2005, Advanced glycation end products (AGEs) and diabetic vascular complications, Curr. Diabetes Rev., 1, 93, 10.2174/1573399052952631 · DOI · Paper page
  18. Nguyen, D.V., Shaw, L.C., and Grant, M.B. (2012). Inflammation in the pathogenesis of microvascular complications in diabetes. Front. Endocrinol., 3. · DOI · Paper page
  19. Penn, 2008, Vascular endothelial growth factor in eye disease, Prog. Retin. Eye Res., 27, 331, 10.1016/j.preteyeres.2008.05.001 · DOI · Paper page
  20. Geraldes, 2010, Activation of protein kinase C isoforms and its impact on diabetic complications, Circ. Res., 106, 1319, 10.1161/CIRCRESAHA.110.217117 · DOI · Paper page
  21. Pan, D., Xu, L., and Guo, M. (2022). The role of protein kinase C in diabetic microvascular complications. Front. Endocrinol., 13. · DOI
  22. Zochodne, 2008, Diabetic polyneuropathy: An update, Curr. Opin. Neurol., 21, 527, 10.1097/WCO.0b013e32830b84cb · DOI
  23. Reddy, 2013, Epigenetic modifications in the pathogenesis of diabetic nephropathy, Semin. Nephrol., 33, 341, 10.1016/j.semnephrol.2013.05.006 · DOI
  24. Brasacchio, 2009, Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail, Diabetes, 58, 1229, 10.2337/db08-1666 · DOI · Paper page
  25. Feng, 2016, miR-200b Mediates Endothelial-to-Mesenchymal Transition in Diabetic Cardiomyopathy, Diabetes, 65, 768, 10.2337/db15-1033 · DOI
  26. Putta, 2012, Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy, J. Am. Soc. Nephrol., 23, 458, 10.1681/ASN.2011050485 · DOI · Paper page
  27. Yan, 2014, Aberrant expression of long noncoding RNAs in early diabetic retinopathy, Investig. Ophthalmol. Vis. Sci., 55, 941, 10.1167/iovs.13-13221 · DOI · Paper page
  28. Zampetaki, 2010, Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes, Circ. Res., 107, 810, 10.1161/CIRCRESAHA.110.226357 · DOI · Paper page
  29. Tang, 2017, Increased Trimethylamine N-Oxide Portends High Mortality Risk Independent of Glycemic Control in Patients with Type 2 Diabetes Mellitus, Clin. Chem., 63, 297, 10.1373/clinchem.2016.263640 · DOI · Paper page
  30. Zhao, 2013, The gut microbiota and obesity: From correlation to causality, Nat. Rev. Microbiol., 11, 639, 10.1038/nrmicro3089 · DOI · Paper page
  31. Shah, J., Cheong, Z.Y., Tan, B., Wong, D., Liu, X., and Chua, J. (2022). Dietary Intake and Diabetic Retinopathy: A Systematic Review of the Literature. Nutrients, 14. · DOI
  32. Wang, W., and Lo, A.C.Y. (2018). Diabetic Retinopathy: Pathophysiology and Treatments. Int. J. Mol. Sci., 19. · DOI · Paper page
  33. Rodriguez, 2019, Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies, Oxidative Med. Cell. Longev., 2019, 4940825, 10.1155/2019/4940825 · DOI · Paper page
  34. Kupis, 2022, Novel therapies for diabetic retinopathy, Cent. Eur. J. Immunol., 47, 102, 10.5114/ceji.2022.112993 · DOI
  35. Kastelan, S., Oreskovic, I., Biscan, F., Kastelan, H., and Gverovic Antunica, A. (2020). Inflammatory and angiogenic biomarkers in diabetic retinopathy. Biochem. Med., 30. · DOI · Paper page
  36. Thomas, 2019, IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018, Diabetes Res. Clin. Pract., 157, 107840, 10.1016/j.diabres.2019.107840 · DOI · Paper page
  37. Forrester, J.V., Kuffova, L., and Delibegovic, M. (2020). The Role of Inflammation in Diabetic Retinopathy. Front. Immunol., 11. · DOI · Paper page
  38. Tang, 2011, Inflammation in diabetic retinopathy, Prog. Retin. Eye Res., 30, 343, 10.1016/j.preteyeres.2011.05.002 · DOI · Paper page
  39. Santiago, A.R., Boia, R., Aires, I.D., Ambrosio, A.F., and Fernandes, R. (2018). Sweet Stress: Coping With Vascular Dysfunction in Diabetic Retinopathy. Front. Physiol., 9. · DOI
  40. Altmann, C., and Schmidt, M.H.H. (2018). The Role of Microglia in Diabetic Retinopathy: Inflammation, Microvasculature Defects and Neurodegeneration. Int. J. Mol. Sci., 19. · DOI · Paper page
  41. Whitehead, 2018, Diabetic retinopathy: A complex pathophysiology requiring novel therapeutic strategies, Expert. Opin. Biol. Ther., 18, 1257, 10.1080/14712598.2018.1545836 · DOI · Paper page
  42. Kastelan, 2013, Inflammation and pharmacological treatment in diabetic retinopathy, Mediat. Inflamm., 2013, 213130, 10.1155/2013/213130 · DOI
  43. Gouliopoulos, 2018, Association of serum inflammatory markers and diabetic retinopathy: A review of literature, Eur. Rev. Med. Pharmacol. Sci., 22, 7113
  44. Yang, J., and Liu, Z. (2022). Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy. Front. Endocrinol., 13. · DOI · Paper page
  45. Fu, 2019, Dyslipidemia in retinal metabolic disorders, EMBO Mol. Med., 11, e10473, 10.15252/emmm.201910473 · DOI
  46. Lu, 2018, Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review, J. Ophthalmol., 2018, 1694187
  47. Sweeney, M., and Foldes, G. (2018). It Takes Two: Endothelial-Perivascular Cell Cross-Talk in Vascular Development and Disease. Front. Cardiovasc. Med., 5. · DOI · Paper page
  48. Hernandez, 2019, Diabetic Retinopathy in the Context of Patients with Diabetes, Ophthalmic Res., 62, 211, 10.1159/000499541 · DOI · Paper page
  49. Stitt, 2016, The progress in understanding and treatment of diabetic retinopathy, Prog. Retin. Eye Res., 51, 156, 10.1016/j.preteyeres.2015.08.001 · DOI · Paper page
  50. Maniadakis, 2019, Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review, Pharmacoeconomics, 37, 995, 10.1007/s40273-019-00800-w · DOI
  51. Alam, S., Sarker, M.M.R., Sultana, T.N., Chowdhury, M.N.R., Rashid, M.A., Chaity, N.I., Zhao, C., Xiao, J., Hafez, E.E., and Khan, S.A. (2022). Antidiabetic Phytochemicals From Medicinal Plants: Prospective Candidates for New Drug Discovery and Development. Front. Endocrinol., 13. · DOI · Paper page
  52. Aryaeian, 2017, Polyphenols and their effects on diabetes management: A review, Med. J. Islam. Repub. Iran., 31, 134, 10.14196/mjiri.31.134 · DOI · Paper page
  53. Delmas, D., Cornebise, C., Courtaut, F., Xiao, J., and Aires, V. (2021). New Highlights of Resveratrol: A Review of Properties against Ocular Diseases. Int. J. Mol. Sci., 22. · DOI
  54. Wang, 2022, Role of Oxidative Stress in Retinal Disease and the Early Intervention Strategies: A Review, Oxid. Med. Cell. Longev., 2022, 7836828, 10.1155/2022/7836828 · DOI
  55. Kang, Q., and Yang, C. (2020). Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol., 37. · DOI · Paper page
  56. Keegan, 2020, Lutein and zeaxanthin attenuates VEGF-induced neovascularisation in human retinal microvascular endothelial cells through a Nox4-dependent pathway, Exp. Eye Res., 197, 108104, 10.1016/j.exer.2020.108104 · DOI
  57. Mthembu, 2023, Sulforaphane: A nutraceutical against diabetes-related complications, Pharmacol. Res., 196, 106918, 10.1016/j.phrs.2023.106918 · DOI
  58. Tanito, 2005, Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice, Investig. Ophthalmol. Vis. Sci., 46, 979, 10.1167/iovs.04-1120 · DOI · Paper page
  59. Valle, 2021, Protective role of vitamin D against oxidative stress in diabetic retinopathy, Diabetes Metab. Res. Rev., 37, e3447, 10.1002/dmrr.3447 · DOI
  60. Fernandez-Robredo, P., Gonzalez-Zamora, J., Recalde, S., Bilbao-Malave, V., Bezunartea, J., Hernandez, M., and Garcia-Layana, A. (2020). Vitamin D Protects against Oxidative Stress and Inflammation in Human Retinal Cells. Antioxidants, 9. · DOI
  61. Putz, 2022, Vitamin D in the Prevention and Treatment of Diabetic Neuropathy, Clin. Ther., 44, 813, 10.1016/j.clinthera.2022.03.012 · DOI
  62. Totolici, 2022, The role of vitamin D in the onset and progression of diabetic retinopathy, Rom. J. Ophthalmol., 66, 214
  63. Jiang, 2017, Epac1 Blocks NLRP3 Inflammasome to Reduce IL-1beta in Retinal Endothelial Cells and Mouse Retinal Vasculature, Mediat. Inflamm., 2017, 2860956, 10.1155/2017/2860956 · DOI
  64. Gu, 2022, Targeting Pyroptosis: New Insights into the Treatment of Diabetic Microvascular Complications, Evid.-Based Complement. Alternat Med., 2022, 5277673, 10.1155/2022/5277673 · DOI
  65. Zhang, 2023, Long noncoding RNA KCNQ1OT1 induces pyroptosis in diabetic corneal endothelial keratopathy, Am. J. Physiol.-Cell Physiol., 318, C346, 10.1152/ajpcell.00053.2019 · DOI
  66. Chen, 2020, The potential role of lncRNAs in diabetes and diabetic microvascular complications, Endocr. J., 67, 659, 10.1507/endocrj.EJ19-0574 · DOI
  67. Zhu, 2016, Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression, Biochem. Biophys. Res. Commun., 469, 319, 10.1016/j.bbrc.2015.11.048 · DOI
  68. You, 2016, Downregulation of Long Noncoding RNA Meg3 Affects Insulin Synthesis and Secretion in Mouse Pancreatic Beta Cells, J. Cell. Physiol., 231, 852, 10.1002/jcp.25175 · DOI · Paper page
  69. Akerman, 2017, Human Pancreatic beta Cell lncRNAs Control Cell-Specific Regulatory Networks, Cell Metab., 25, 400, 10.1016/j.cmet.2016.11.016 · DOI · Paper page
  70. Callaghan, 2015, Distal Symmetric Polyneuropathy: A Review, JAMA, 314, 2172, 10.1001/jama.2015.13611 · DOI · Paper page
  71. Callaghan, 2014, Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy, JAMA Neurol., 71, 1143, 10.1001/jamaneurol.2014.1279 · DOI · Paper page
  72. Yang, H., Sloan, G., Ye, Y., Wang, S., Duan, B., Tesfaye, S., and Gao, L. (2019). New Perspective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine. Front. Endocrinol., 10. · DOI · Paper page
  73. Ling, 2020, The impact of diabetic foot ulcers and unilateral offloading footwear on gait in people with diabetes, Clin. Biomech., 73, 157, 10.1016/j.clinbiomech.2020.01.014 · DOI
  74. Miyashita, A., Kobayashi, M., Yokota, T., and Zochodne, D.W. (2023). Diabetic Polyneuropathy: New Strategies to Target Sensory Neurons in Dorsal Root Ganglia. Int. J. Mol. Sci., 24. · DOI
  75. Ishibashi, 2019, Improvement in Neuropathy Outcomes with Normalizing HbA(1c) in Patients with Type 2 Diabetes, Diabetes Care, 42, 110, 10.2337/dc18-1560 · DOI
  76. Veluchamy, 2017, Risk factors for neuropathic pain in diabetes mellitus, Pain, 158, 560, 10.1097/j.pain.0000000000000785 · DOI · Paper page
  77. Raputova, 2017, Sensory phenotype and risk factors for painful diabetic neuropathy: A cross-sectional observational study, Pain, 158, 2340, 10.1097/j.pain.0000000000001034 · DOI · Paper page
  78. Kim, 2012, Emerging therapy for diabetic neuropathy: Cell therapy targeting vessels and nerves, Endocr. Metab. Immune Disord. Drug Targets, 12, 168, 10.2174/187153012800493486 · DOI
  79. Komai, 2024, Vascular Disease and Diabetes, Ann. Vasc. Dis., 17, 109, 10.3400/avd.ra.24-00010 · DOI
  80. Zochodne, 2015, Diabetes and the plasticity of sensory neurons, Neurosci. Lett., 596, 60, 10.1016/j.neulet.2014.11.017 · DOI
  81. Sugimoto, 2002, Expression and localization of insulin receptor in rat dorsal root ganglion and spinal cord, J. Peripher. Nerv. Syst., 7, 44, 10.1046/j.1529-8027.2002.02005.x · DOI
  82. Zochodne, 1999, Diabetic neuropathies: Features and mechanisms, Brain Pathol., 9, 369, 10.1111/j.1750-3639.1999.tb00233.x · DOI · Paper page
  83. Pop-Busui, R., Ang, L., Boulton, A.J.M., Feldman, E.L., Marcus, R.L., Mizokami-Stout, K., Singleton, J.R., and Ziegler, D. (2022). Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy, American Diabetes Association. · DOI · Paper page
  84. Callaghan, 2012, Enhanced glucose control for preventing and treating diabetic neuropathy, Cochrane Database Syst. Rev., 6, CD007543
  85. Page, 2012, Clinical inquiry: What medications are best for diabetic neuropathic pain?, J. Fam. Pract., 61, 691
  86. Akter, S., Choubey, M., Mohib, M.M., Arbee, S., Sagor, M.A.T., and Mohiuddin, M.S. (2023). Stem Cell Therapy in Diabetic Polyneuropathy: Recent Advancements and Future Directions. Brain Sci., 13. · DOI
  87. Voute, 2021, Topical Lidocaine for Chronic Pain Treatment, Drug Des. Devel Ther., 15, 4091, 10.2147/DDDT.S328228 · DOI
  88. Volmer-Thole, M., and Lobmann, R. (2016). Neuropathy and Diabetic Foot Syndrome. Int. J. Mol. Sci., 17. · DOI · Paper page
  89. Cernea, 2021, Management of diabetic neuropathy, Metabolism, 123, 154867, 10.1016/j.metabol.2021.154867 · DOI
  90. Singh, 2014, Regeneration of diabetic axons is enhanced by selective knockdown of the PTEN gene, Brain, 137, 1051, 10.1093/brain/awu031 · DOI
  91. Cheng, 2017, A model of chronic diabetic polyneuropathy: Benefits from intranasal insulin are modified by sex and RAGE deletion, Am. J. Physiol. Endocrinol. Metab., 312, E407, 10.1152/ajpendo.00444.2016 · DOI
  92. Kobayashi, 2017, Diabetic polyneuropathy, sensory neurons, nuclear structure and spliceosome alterations: A role for CWC22, Dis. Model. Mech., 10, 215, 10.1242/dmm.028225 · DOI
  93. Chandrasekhar, 2021, Dual Specificity Phosphatases Support Axon Plasticity and Viability, Mol. Neurobiol., 58, 391, 10.1007/s12035-020-02119-6 · DOI
  94. Kaburagi, 2022, Systemic DNA/RNA heteroduplex oligonucleotide administration for regulating the gene expression of dorsal root ganglion and sciatic nerve, Mol. Ther. Nucleic Acids, 28, 910, 10.1016/j.omtn.2022.05.006 · DOI
  95. Kapranov, 2007, RNA maps reveal new RNA classes and a possible function for pervasive transcription, Science, 316, 1484, 10.1126/science.1138341 · DOI · Paper page
  96. Yao, 2022, Long non-coding RNA MALAT1 regulates retinal neurodegeneration through CREB signaling, EMBO Mol. Med., 14, e16660, 10.15252/emmm.202216660 · doi:10.15252/emmm.202216660
  97. Wu, 2020, Long non-coding RNA MALAT1 promotes the proliferation and migration of Schwann cells by elevating BDNF through sponging miR-129-5p, Exp. Cell Res., 390, 111937, 10.1016/j.yexcr.2020.111937 · DOI
  98. Radhakrishnan, 2021, Long Noncoding RNA MALAT1 and Regulation of the Antioxidant Defense System in Diabetic Retinopathy, Diabetes, 70, 227, 10.2337/db20-0375 · DOI
  99. Arunkumar, 2024, LncRNAs: The good, the bad, and the unknown, Biochem. Cell Biol., 102, 9, 10.1139/bcb-2023-0155 · DOI
  100. Hussein, 2023, Long non-coding RNAs: The hidden players in diabetes mellitus-related complications, Diabetes Metab. Syndr., 17, 102872, 10.1016/j.dsx.2023.102872 · DOI
  101. Ebrahimi, 2021, Therapeutic effects of stem cells in different body systems, a novel method that is yet to gain trust: A comprehensive review, Bosn. J. Basic. Med. Sci., 21, 672
  102. Kubiak, 2020, Stem-cell-based therapies to enhance peripheral nerve regeneration, Muscle Nerve, 61, 449, 10.1002/mus.26760 · DOI · Paper page
  103. Streckmann, 2022, Exercise and Neuropathy: Systematic Review with Meta-Analysis, Sports Med., 52, 1043, 10.1007/s40279-021-01596-6 · DOI
  104. Dagar, 2021, Diabetic nephropathy: A twisted thread to unravel, Life Sci., 278, 119635, 10.1016/j.lfs.2021.119635 · DOI
  105. Umanath, 2018, Update on Diabetic Nephropathy: Core Curriculum 2018, Am. J. Kidney Dis., 71, 884, 10.1053/j.ajkd.2017.10.026 · DOI · Paper page
  106. Paschou, 2018, Diabetic nephropathy in type 1 diabetes, Minerva Med., 109, 218
  107. Koch, 2020, Autophagy in diabetic nephropathy: A review, Int. Urol. Nephrol., 52, 1705, 10.1007/s11255-020-02545-4 · DOI
  108. Ying, 2022, Diabetes and other vascular risk factors in association with the risk of lower extremity amputation in chronic limb-threatening ischemia: A prospective cohort study, Cardiovasc. Diabetol., 21, 7, 10.1186/s12933-021-01441-0 · DOI
  109. Giri, 2018, Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity, Biomed. Pharmacother., 107, 306, 10.1016/j.biopha.2018.07.157 · DOI · Paper page
  110. Calle, P., and Hotter, G. (2020). Macrophage Phenotype and Fibrosis in Diabetic Nephropathy. Int. J. Mol. Sci., 21. · DOI · Paper page
  111. Mussap, 2005, Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes, J. Am. Soc. Nephrol., 16, S78, 10.1681/ASN.2004110961 · DOI · Paper page
  112. Wada, 2013, Inflammation and the pathogenesis of diabetic nephropathy, Clin. Sci., 124, 139, 10.1042/CS20120198 · DOI · Paper page
  113. Gupta, 2023, Diabetic Kidney Disease: An Update, Med. Clin. N. Am., 107, 689, 10.1016/j.mcna.2023.03.004 · DOI · Paper page
  114. Landstra, C.P., and de Koning, E.J.P. (2021). COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course. Front. Endocrinol., 12. · DOI · Paper page
  115. Salom, 2017, Natural antioxidants in the treatment and prevention of diabetic nephropathy; a potential approach that warrants clinical trials, Redox Rep., 22, 99, 10.1080/13510002.2017.1297885 · DOI
  116. Jia, 2019, Genistein attenuates renal fibrosis in streptozotocin-induced diabetic rats, Mol. Med. Rep., 19, 423
  117. Lachin, 2021, Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC), Diabetes Care, 44, 2216, 10.2337/dc20-3097 · DOI · Paper page
  118. Ahmad, 2015, Management of diabetic nephropathy: Recent progress and future perspective, Diabetes Metab. Syndr., 9, 343, 10.1016/j.dsx.2015.02.008 · DOI
  119. Cha, 2021, Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes, J. Clin. Endocrinol. Metab., 106, 1225, 10.1210/clinem/dgaa894 · DOI
  120. Tanase, D.M., Gosav, E.M., Anton, M.I., Floria, M., Seritean Isac, P.N., Hurjui, L.L., Tarniceriu, C.C., Costea, C.F., Ciocoiu, M., and Rezus, C. (2022). Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives. Biomolecules, 12. · DOI · Paper page
  121. Charlton, A., Garzarella, J., Jandeleit-Dahm, K.A.M., and Jha, J.C. (2020). Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes. Biology, 10. · DOI · Paper page
  122. Eltablawy, 2018, Vitamin D protection from rat diabetic nephropathy is partly mediated through Klotho expression and renin-angiotensin inhibition, Arch. Physiol. Biochem., 124, 461, 10.1080/13813455.2018.1423624 · DOI
  123. Ma, 2010, Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status, Br. J. Pharmacol., 160, 1273, 10.1111/j.1476-5381.2010.00750.x · DOI · Paper page
  124. Mazzieri, A., Porcellati, F., Timio, F., and Reboldi, G. (2024). Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection. Int. J. Mol. Sci., 25. · DOI
  125. Zhang, 2018, The Long Noncoding RNA 150Rik Promotes Mesangial Cell Proliferation via miR-451/IGF1R/p38 MAPK Signaling in Diabetic Nephropathy, Cell Physiol. Biochem., 51, 1410, 10.1159/000495590 · doi:10.1159/000495590
  126. Huang, 2019, Long noncoding RNA NEAT1 accelerates the proliferation and fibrosis in diabetic nephropathy through activating Akt/mTOR signaling pathway, J. Cell Physiol., 234, 11200, 10.1002/jcp.27770 · DOI
  127. Mao, 2019, Astragaloside IV inhibits excessive mesangial cell proliferation and renal fibrosis caused by diabetic nephropathy via modulation of the TGF-beta1/Smad/miR-192 signaling pathway, Exp. Ther. Med., 18, 3053
  128. Hanson, 2007, Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study, Diabetes, 56, 975, 10.2337/db06-1072 · DOI
  129. Lin, B., Ma, Y.Y., and Wang, J.W. (2022). Nano-Technological Approaches for Targeting Kidney Diseases With Focus on Diabetic Nephropathy: Recent Progress, and Future Perspectives. Front. Bioeng. Biotechnol., 10. · DOI
  130. Ramos, 2020, Design and optimization strategies for the development of new drugs that treat chronic kidney disease, Expert. Opin. Drug Discov., 15, 101, 10.1080/17460441.2020.1690450 · DOI
  131. Faustino, C., and Pinheiro, L. (2020). Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy. Pharmaceutics, 12. · DOI · Paper page
  132. Rubin, 2020, Improving Molecular Therapy in the Kidney, Mol. Diagn. Ther., 24, 375, 10.1007/s40291-020-00467-6 · DOI
  133. Boonstra, 2018, Local delivery of liposomal prednisolone leads to an anti-inflammatory profile in renal ischaemia-reperfusion injury in the rat, Nephrol. Dial. Transplant., 33, 44, 10.1093/ndt/gfx204 · DOI
  134. Tandon, 2012, Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: Implications of the results of recent clinical trials in type 2 diabetes, Am. J. Cardiovasc. Drugs, 12, 7, 10.2165/11594650-000000000-00000 · DOI
  135. Milligan, 2016, Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation, J. Diabetes Complicat., 30, 1177, 10.1016/j.jdiacomp.2016.03.010 · DOI
  136. Tilinca, M.C., Tiuca, R.A., Tilea, I., and Varga, A. (2021). The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. J. Pers. Med., 11. · DOI
  137. Hussain, 2019, The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus, Drugs, 79, 231, 10.1007/s40265-019-1061-4 · DOI
  138. Wronka, M., Krzemińska, J., Młynarska, E., Rysz, J., and Franczyk, B. (2023). New Insights into the Use of Liraglutide-Impact on Cardiovascular Risk and Microvascular Outcomes. Biomedicines, 11. · DOI

Cited by

See all 64

Metadata

Authors
Yapislar, H., & Gurler, E. B.
Venue
Biomedicines
Publisher
MDPI AG
Published
2024-08-28
Volume
12
Issue
9
Pages
1958
ISSN
2227-9059
Cited by
64
References
24
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment. https://app.cochat.ai/papers/10.3390/biomedicines12091958
The paper
Yapislar, H., & Gurler, E. B. (2024). Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment. Biomedicines. https://doi.org/10.3390/biomedicines12091958

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.